STOCK TITAN

Armata Pharmaceuticals posts $54.9M Q3 2026 profit

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Armata Pharmaceuticals, Inc. (ARMP) reported third-quarter 2026 net income of $54.9 million, compared with a $26.7 million net loss a year earlier. The result was primarily driven by a $69.6 million gain from the change in fair value of its convertible loan; operating loss was $7.4 million versus $7.8 million. Grant and award revenue was $3.2 million, compared with $1.2 million, while research and development expenses were $6.8 million versus $5.8 million.

Cash and cash equivalents were $18.3 million at September 30, 2026, compared with $8.7 million at December 31, 2025; net cash used in operating activities for the first nine months was $20.0 million. Armata said preparations continued for its planned AP-SA02 Phase 3 superiority study for complicated Staphylococcus aureus bacteremia. The study was expected to initiate in the second half of 2026, with exact timing depending on FDA concurrence with the protocol. AP-SA02 has FDA Breakthrough Therapy designation.

2 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Major pointThird-quarter net income: $54.9 million, versus a $26.7 million loss, primarily driven by the convertible-loan fair-value gain.
  • Moderate pointGrant and award revenue: $3.2 million, versus $1.2 million in Q3 2025.

Negative

  • None.

Filing Explained

At September 30, current liabilities included $94,309 thousand of convertible loan and $83,862 thousand of term debt.

This Form 8-K reports Armata’s third-quarter results; its September 30 balance sheet lists the convertible loan and term debt as current liabilities, whereas both appeared as non-current liabilities at December 31, 2025. It reports $94,309 thousand of current convertible loan and $83,862 thousand of current term debt, with a further $43,299 thousand of non-current term debt.

The results statement separately reports $54,857 thousand of net income, $12,219 thousand attributed to participating warrants, and $42,638 thousand attributable to common stockholders.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Net income (loss) $54.9 million Three months ended September 30, 2026; compared with a net loss of $26.7 million in 2025
Convertible-loan fair-value gain $69.6 million Three months ended September 30, 2026
Grant and award revenue $3.2 million Three months ended September 30, 2026; compared with $1.2 million in 2025
Research and development expenses $6.8 million Three months ended September 30, 2026; compared with $5.8 million in 2025
General and administrative expenses $3.7 million Three months ended September 30, 2026; compared with $3.1 million in 2025
Operating loss $7.4 million Three months ended September 30, 2026; compared with $7.8 million in 2025
Cash and cash equivalents $18.3 million As of September 30, 2026
Net cash used in operating activities $20.0 million Nine months ended September 30, 2026
bacteriophage therapeutics medical
"development of high-purity and potent, pathogen-specific bacteriophage therapeutics"
Bacteriophage therapeutics are medicines made from viruses that specifically infect and kill bacteria; think of them as guided missiles that seek out harmful bacteria rather than blanket antibiotics that act like area bombs. They matter to investors because they offer a potential solution to antibiotic resistance and could open new markets, but they also carry development and regulatory uncertainty, complex manufacturing needs, and reimbursement risk that can affect commercial prospects.
Phase 3 superiority study medical
"planned pivotal Phase 3 superiority study of AP-SA02"
Biologics License Application (BLA) regulatory
"support a future Biologics License Application (BLA) for AP-SA02"
A biologics license application (BLA) is a formal request to a government agency seeking approval to sell a biological medicine, such as vaccines or gene therapies, in the market. It is similar to a detailed report that proves the product is safe, effective, and manufactured properly. For investors, a BLA signifies a critical step toward commercial availability, often impacting a company's valuation and market prospects.
Breakthrough Therapy designation regulatory
"FDA’s recent Breakthrough Therapy designation"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
Qualified Infectious Disease Product (QIDP) regulatory
"received Qualified Infectious Disease Product (QIDP)"
A qualified infectious disease product (QIDP) is a drug or antibiotic given a special regulatory label because it treats serious bacterial or fungal infections. The label brings incentives—such as faster regulatory review and extra time before generic competitors can enter—that make it easier and potentially more profitable for developers. Investors watch QIDP status because it can speed a product to market and extend exclusive sales, boosting revenue prospects.
change in fair value financial
"gain of $69.6 million from the change in fair value of the convertible loan"
Grant and award revenue $3.2 million Compared with $1.2 million in 2025
Research and development expenses $6.8 million Compared with $5.8 million in 2025
General and administrative expenses $3.7 million Compared with $3.1 million in 2025
Operating loss $7.4 million Compared with $7.8 million in 2025
Other income (expense), net $62.2 million income Compared with $18.9 million expense in 2025
Net income (loss) $54.9 million Compared with a $26.7 million net loss in 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ARMP report for third-quarter 2026 net income?

Armata reported net income of $54.9 million, compared with a $26.7 million net loss in the third quarter of 2025. The 2026 result was primarily driven by a $69.6 million gain from the change in fair value of the convertible loan.

When is ARMP's AP-SA02 Phase 3 study expected to start?

Armata expected its planned AP-SA02 Phase 3 superiority study to initiate in the second half of 2026, with exact timing depending on when the FDA concurs with the protocol. The study is designed to support a future Biologics License Application.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000092111400009211142026-11-122026-11-12

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 12, 2026

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

​

Washington

001-37544

91-1549568

(State or other jurisdiction of
incorporation or organization)

(Commission File Number)

(IRS Employer Identification No.)

​

​

​

​

​

​

5005 McConnell Avenue

Los Angeles, California

​

90066

(Address of principal executive offices)

(Zip Code)

​

(310) 665-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

​

Title of Each Class

  ​ ​ ​

Trading Symbol(s)

  ​ ​ ​

Name of Each Exchange on Which Registered

Common Stock

​

ARMP

​

NYSE American

​

​

​

​

​

​

Item 2.02Results of Operations and Financial Condition.

​

On November 12, 2026, the Company announced its financial results for the three and nine months ended September 30, 2026, in the press release furnished hereto as Exhibit 99.1.

​

The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

​

Item 9.01Financial Statements and Exhibits.

​

(d)Exhibits.

​

​

​

​

Exhibit
No.

  ​ ​ ​

Description

99.1

​

Press Release, dated November 12, 2026.

104

​

Cover Page Interactive Data File (embedded within Inline XBRL document).

​

​

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

Date: November 12, 2026

Armata Pharmaceuticals, Inc.

​

​

​

By:

/s/ David House

​

Name:

David House

​

Title:

Chief Financial Officer

(Principal Financial Officer)

​

Exhibit 99.1

Graphic

​

Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update

​

LOS ANGELES, Calif., November 12, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2026, and provided a corporate update.

​

“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02,” said Armata’s Dr. Deborah Birx, Chief Executive Officer. “We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study. Our manufacturing capabilities are well established, critical clinical trial preparations are progressing, and we continue to work closely with the U.S. Food and Drug Administration (“FDA”) to finalize the study design. Together, these accomplishments reflect the considerable effort and investment we have made to prepare for this important next stage of development, while maintaining fiscal discipline.”

​

“We believe the FDA’s recent Breakthrough Therapy designation further underscores AP-SA02’s clinical potential. We also appreciate the continued financial support of the U.S. Department of War (“DoW”), which comes at an important time as we prepare for this next critical stage of clinical development. We believe AP-SA02 has the potential to make a meaningful difference in patient care and, more broadly, provide a foundation for expanding our bacteriophage technology into additional indications. We are excited about the opportunity ahead and remain firmly focused on successfully executing our Phase 3 program,” concluded Dr. Birx.

​

Third Quarter 2026 and Recent Developments:

​

Preparations for AP-SA02 Phase 3 Program

​

Armata continued to make significant progress in clinical, regulatory, manufacturing, and operational preparations for the planned pivotal Phase 3 superiority study of AP-SA02, the Company’s intravenously administered multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia (“SAB”) caused by methicillin-sensitive S. aureus (“MSSA”) or methicillin-resistant S. aureus (“MRSA”).

​

●Continued discussions with the FDA to finalize the study design and submitted protocol revisions in response to FDA feedback.
●Submitted responses to all Clinical, Chemistry, Manufacturing, and Controls (“CMC”), and Regulatory comments in the FDA’s End-of-Phase 2 meeting written response.
●Completed four engineering runs of AP-SA02 at the Company’s in-house cGMP manufacturing facility in Los Angeles, California. Production of clinical trial material for the planned Phase 3 study is underway, with one cGMP production run and vialing of AP-SA02 drug product completed in the third quarter of 2026.
●Advanced the qualification and validation of quality control release assays.
●Completed validation of critical utilities.
●Executed contracts with clinical research organizations to support study management.
●Continued negotiating clinical trial agreements with an initial group of U.S. clinical trial sites.

​


Graphic

​

Collectively, these activities advance the Company’s preparations to initiate its planned pivotal Phase 3 superiority study, which is designed to support a future Biologics License Application (BLA) for AP-SA02. The Phase 3 study is expected to initiate in the second half of 2026, with exact timing depending on when FDA concurs with the protocol.

​

Regulatory

​

●Received FDA Breakthrough Therapy designation for AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA. The designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have shown preliminary clinical evidence indicating the potential for substantial improvement over available therapies. AP-SA02 now holds Breakthrough Therapy, Fast Track and Qualified Infectious Disease Product designations, providing strong regulatory validation.
●Obtained FDA agreement on an Initial Pediatric Study Plan (“Agreed iPSP”) for future pediatric evaluation of AP-SA02 as an adjunct treatment for complicated SAB, with pediatric studies deferred pending safety and efficacy data from the planned adult Phase 3 program. We believe this plan supports potential pediatric expansion while prioritizing patient safety and efficient clinical development.

​

Funding

​

●Received $3.7 million in additional non-dilutive funding from the DoWi, the first funds received specifically for AP-SA02 Phase 3 execution under a previously announced award. This brings cumulative non-dilutive DoW funding under the award to approximately $32.4 million, including $28.7 million previously provided, underscoring continued U.S. government’s interest in advancing AP-SA02.

​

Presentations and Publications

​

●Presented new AP-SA02 data at the 20th International Symposium on Staphylococci and Staphylococcal Infections (ISSSI), held September 20–24 in Banff, Alberta, Canada. Findings suggest controlled genetic diversity may enhance killing of certain S. aureus clinical isolates by enabling individual phages to adapt to genetically and geographically diverse MRSA and MSSA isolates.
●Further advanced bacteriophage science through publication of the peer-reviewed article "Insights into Genome Ejection by a Therapeutic phiKMV-like Bacteriophage" in the Journal of Molecular Biology.
●Participated in the H.C. Wainwright 28th Annual Global Investment Conference.

​

Intellectual Property

​

●Announced the issuance of two U.S. patents covering the Company's bacteriophage programs:
oU.S. Patent No. 12,751,983, issued October 6, 2026, protects methods of treating S. aureus infections with AP-SA02, with protection until at least February 2041.
oU.S. Patent No. 12,594,312, issued April 7, 2026, protects methods of treating Pseudomonas infections with AP-PA02, with protection expected until January 2043.

​


Graphic

​

Third Quarter 2026 Financial Results

​

Grant and Award Revenue. The Company recognized grant and award revenue of $3.2 million for the three months ended September 30, 2026, as compared to $1.2 million in the comparable period in 2025. This represents the Medical Technology Enterprise Consortium's share of the costs incurred for the Company's AP-SA02 program for the treatment of SAB.

​

Research and Development. Research and development expenses for the three months ended September 30, 2026 were approximately $6.8 million, compared to approximately $5.8 million for the comparable period in 2025.

​

General and Administrative. General and administrative expenses for the three months ended September 30, 2026 were approximately $3.7 million, compared to approximately $3.1 million for the comparable period in 2025.

​

Loss from Operations. Loss from operations for the three months ended September 30, 2026 was approximately $7.4 million, compared to a loss of approximately $7.8 million for the comparable period in 2025.

​

Other Income (Expense). Other income, net, for the three months ended September 30, 2026 was approximately $62.2 million, compared with other expense, net, of approximately $18.9 million for the comparable period in 2025. Other income, net for the three months ended September 30, 2026 and 2025 included a gain of $69.6 million and a loss of $14.6 million, respectively, from changes in the fair value of the convertible loan.

​

Net Income (Loss). The net income for the third quarter of 2026 was $54.9 million, or $1.15 earnings per share on a basic basis and a ($0.24) loss per share on a diluted basis, as compared to a net loss of ($26.7) million, or ($0.74) loss per share on a basic and diluted basis, for the comparable period in 2025. Net income for the three months ended September 30, 2026 was primarily driven by the gain of $69.6 million from the change in fair value of the convertible loan.

​

Cash and Cash Equivalents. As of September 30, 2026, Armata held approximately $18.3 million of unrestricted cash and cash equivalents, compared to $8.7 million as of December 31, 2025.

​

As of November 6, 2026, 37,192,632 common shares were outstanding.

​

About AP-SA02

​

Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). AP-SA02 has received Qualified Infectious Disease Product (QIDP), Fast Track and Breakthrough Therapy designations from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy (“BAT”) compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. The Company highlighted positive results from the Phase 2a diSArm study in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, anticipated to initiate in the second half of 2026, with exact timing depending on when FDA concurs with the protocol.


Graphic

​

​

About Armata Pharmaceuticals, Inc.

​

Armata is a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic, including in-house phage-specific current Good Manufacturing Practices (“cGMP”) manufacturing to support full commercialization.

​

Forward-Looking Statements

​

This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; Armata’s planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the U.S. Securities and Exchange Commission (the “SEC”), including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

​

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

​

Media Contacts:

​

At Armata:

​

Pierre Kyme

ir@armatapharma.com

310-665-2928

​


Graphic

​

Investor Relations:

​

Joyce Allaire

LifeSci Advisors, LLC

jallaire@lifesciadvisors.com

212-915-2569


Graphic

​

Armata Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

September 30, 2026

  ​ ​ ​

December 31, 2025

  ​ ​ ​

Assets

​

​

​

​

​

​

​

Current assets

​

​

​

​

​

​

​

Cash and cash equivalents

​

$

18,317

​

$

8,688

​

Prepaid expenses and other current assets

​

 

1,073

​

 

1,508

​

Other receivables

​

​

3,209

​

​

472

​

Total current assets

​

 

22,599

​

 

10,668

​

Property and equipment, net

​

 

10,799

​

 

12,194

​

Operating lease right-of-use asset

​

 

32,378

​

 

33,911

​

Intangible assets, net

​

​

13,746

​

​

13,746

​

Other long-term assets

​

 

4,956

​

 

6,363

​

Total assets

​

$

84,478

​

$

76,882

​

​

​

​

​

​

​

​

​

Liabilities and stockholders’ deficit

​

 

  ​

​

 

  ​

​

Accounts payable, accrued and other current liabilities

​

$

8,607

​

$

8,947

​

Convertible Loan, current

​

​

94,309

​

​

—

​

Term debt, current

​

​

83,862

​

​

—

​

Total current liabilities

​

186,778

​

8,947

​

Convertible Loan, non-current

​

​

—

​

​

153,860

​

Term debt, non-current

​

​

43,299

​

​

103,061

​

Operating lease liabilities, net of current portion

​

​

25,452

​

​

26,533

​

Deferred tax liability

​

​

3,077

​

​

3,077

​

Total liabilities

​

 

258,606

​

 

295,478

​

Total stockholders’ deficit

​

 

(174,128)

​

 

(218,596)

​

Total liabilities and stockholders’ deficit

​

$

84,478

​

$

76,882

​

​


Graphic

​

Armata Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30,

​

Nine Months Ended September 30,

​

2026

  ​ ​ ​

2025

​

2026

  ​ ​ ​

2025

Grant and award revenue

$

3,171

​

$

1,159

​

$

6,470

​

$

3,819

Operating expenses

​

​

​

​

​

​

​

​

​

​

​

Research and development

 

6,830

​

​

5,824

​

 

20,527

​

​

17,647

General and administrative

 

3,724

​

​

3,111

​

 

12,423

​

​

8,983

Total operating expenses

​

10,554

​

​

8,935

​

​

32,950

​

​

26,630

Operating loss

 

(7,383)

​

 

(7,776)

​

 

(26,480)

​

 

(22,811)

Other income (expense)

 

​

​

 

  ​

​

 

​

​

 

  ​

Interest income

​

206

​

​

90

​

​

335

​

​

257

Interest expense

​

(7,561)

​

​

(4,346)

​

​

(19,754)

​

​

(11,756)

Change in fair value of the Convertible Loan

​

69,595

​

​

(14,643)

​

​

59,551

​

​

(15,191)

Total other income (expense), net

 

62,240

​

 

(18,899)

​

 

40,132

​

 

(26,690)

Net income (loss)

​

54,857

​

​

(26,675)

​

​

13,652

​

​

(49,501)

Income attributable to participating warrants

​

(12,219)

​

​

—

​

​

(3,064)

​

​

—

Net income (loss) attributable to common stockholders

$

42,638

​

$

(26,675)

​

$

10,588

​

$

(49,501)

Per share information:

​

​

​

​

​

​

​

​

​

​

​

Net income (loss) per share, basic

$

1.15

​

$

(0.74)

​

$

0.29

​

$

(1.37)

Weighted average shares outstanding, basic

​

37,181,573

​

​

36,226,285

​

​

36,822,284

​

​

36,201,674

Net loss per share, diluted

$

(0.24)

​

$

(0.74)

​

$

(0.74)

​

$

(1.37)

Weighted average shares outstanding, diluted

​

62,679,380

​

​

36,226,285

​

​

61,923,161

​

​

36,201,674

​

​


Graphic

​

Armata Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Operating activities:

​

​

​

​

​

​

Net income (loss)

​

$

13,652

​

$

(49,501)

Adjustments required to reconcile net income (loss) to net cash used in operating activities:

​

​

​

​

​

​

Depreciation expense

​

 

1,620

​

 

1,113

Stock-based compensation expense

​

​

6,682

​

​

1,978

Change in fair value of the Convertible Loan

​

​

(59,551)

​

​

15,191

Non-cash accrued interest expense

​

​

19,740

​

​

11,739

Change in right-of-use asset

​

​

1,533

​

​

1,770

Changes in operating assets and liabilities:

​

 

(3,640)

​

 

(1,379)

Net cash used in operating activities

​

 

(19,964)

​

 

(19,089)

Investing activities:

​

 

  ​

​

 

  ​

Purchases of property and equipment

​

​

(171)

​

​

(490)

Net cash used in investing activities

​

 

(171)

​

​

(490)

Financing activities:

​

 

  ​

​

 

  ​

Proceeds from issuance of term debt, net of issuance costs

​

​

25,000

​

​

25,000

Proceeds from issuance of common stock under ATM, net

​

​

2,373

​

​

—

Payments for taxes related to net share settlement of equity awards

​

​

(121)

​

​

(46)

Proceeds from exercise of stock options

​

​

1,242

​

​

—

Net cash provided by financing activities

​

 

28,494

​

 

24,954

Net change in cash, cash equivalents and restricted cash

​

 

8,359

​

 

5,375

Cash, cash equivalents and restricted cash, beginning of period

​

 

14,078

​

 

14,771

Cash, cash equivalents and restricted cash, end of period

​

$

22,437

​

$

20,146

​

Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:

​

​

​

​

​

​

​

​

​

​

September 30, 2026

​

September 30, 2025

Cash and cash equivalents

​

$

18,317

​

$

14,756

Restricted cash

​

​

4,120

​

​

5,390

Cash, cash equivalents and restricted cash

​

$

22,437

​

$

20,146

​

i Department of War (DoW) award received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.

​

​

​


Filing Exhibits & Attachments

5 documents

Keep reading